BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37703359)

  • 1. Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC.
    Boslem E; Reibe S; Carlessi R; Smeuninx B; Tegegne S; Egan CL; McLennan E; Terry LV; Nobis M; Mu A; Nowell C; Horadagoda N; Henstridge DC; Mellett NA; Timpson P; Jones M; Denisenko E; Forrest ARR; Tirnitz-Parker JEE; Meikle PJ; Rose-John S; Karin M; Febbraio MA
    Sci Adv; 2023 Sep; 9(37):eadh0831. PubMed ID: 37703359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis.
    He F; Zhang P; Liu J; Wang R; Kaufman RJ; Yaden BC; Karin M
    J Hepatol; 2023 Aug; 79(2):362-377. PubMed ID: 36996941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
    Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?
    Febbraio MA; Reibe S; Shalapour S; Ooi GJ; Watt MJ; Karin M
    Cell Metab; 2019 Jan; 29(1):18-26. PubMed ID: 30449681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
    Povero D; Chen Y; Johnson SM; McMahon CE; Pan M; Bao H; Petterson XT; Blake E; Lauer KP; O'Brien DR; Yu Y; Graham RP; Taner T; Han X; Razidlo GL; Liu J
    J Hepatol; 2023 Aug; 79(2):378-393. PubMed ID: 37061197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation.
    Afrin R; Arumugam S; Rahman A; Wahed MI; Karuppagounder V; Harima M; Suzuki H; Miyashita S; Suzuki K; Yoneyama H; Ueno K; Watanabe K
    Int Immunopharmacol; 2017 Mar; 44():174-182. PubMed ID: 28110063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
    Conde de la Rosa L; Garcia-Ruiz C; Vallejo C; Baulies A; Nuñez S; Monte MJ; Marin JJG; Baila-Rueda L; Cenarro A; Civeira F; Fuster J; Garcia-Valdecasas JC; Ferrer J; Karin M; Ribas V; Fernandez-Checa JC
    J Hepatol; 2021 Jun; 74(6):1429-1441. PubMed ID: 33515644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
    Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
    Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet.
    Okada H; Takabatake R; Honda M; Takegoshi K; Yamashita T; Nakamura M; Shirasaki T; Sakai Y; Shimakami T; Nagata N; Takamura T; Tanaka T; Kaneko S
    Oncotarget; 2017 Jun; 8(25):39978-39993. PubMed ID: 28591717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
    de Oliveira S; Houseright RA; Graves AL; Golenberg N; Korte BG; Miskolci V; Huttenlocher A
    J Hepatol; 2019 Apr; 70(4):710-721. PubMed ID: 30572006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma.
    Green CD; Weigel C; Brown RDR; Bedossa P; Dozmorov M; Sanyal AJ; Spiegel S
    FASEB J; 2022 Jul; 36(7):e22372. PubMed ID: 35639028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
    Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
    Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
    J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypothalamic orexin prevents non-alcoholic steatohepatitis and hepatocellular carcinoma in obesity.
    Tsuneki H; Maeda T; Takata S; Sugiyama M; Otsuka K; Ishizuka H; Onogi Y; Tokai E; Koshida C; Kon K; Takasaki I; Hamashima T; Sasahara M; Rudich A; Koya D; Sakurai T; Yanagisawa M; Yamanaka A; Wada T; Sasaoka T
    Cell Rep; 2022 Oct; 41(3):111497. PubMed ID: 36261021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC.
    Zhang Y; Wang H; Xiao H
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065108
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Li T; Lin X; Shen B; Zhang W; Liu Y; Liu H; Wang Y; Zheng L; Zhi F
    Front Immunol; 2022; 13():1047570. PubMed ID: 36531991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Models of nonalcoholic steatohepatitis potentiated by chemical inducers leading to hepatocellular carcinoma.
    Márquez-Quiroga LV; Arellanes-Robledo J; Vásquez-Garzón VR; Villa-Treviño S; Muriel P
    Biochem Pharmacol; 2022 Jan; 195():114845. PubMed ID: 34801522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Strategies and Mechanisms Associated with the Prevention of NASH-Associated HCC by a Toll-like Receptor 4 Inhibitor.
    Kwan SY; Slayden AN; Coronado AR; Marquez RC; Chen H; Wei P; Savage MI; Vornik LA; Fox JT; Sei S; Liang D; Stevenson HL; Wilkerson GK; Gagea M; Brown PH; Beretta L
    Cancer Prev Res (Phila); 2023 Jan; 16(1):17-28. PubMed ID: 36162136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential methylation patterns in lean and obese non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
    Hymel E; Fisher KW; Farazi PA
    BMC Cancer; 2022 Dec; 22(1):1276. PubMed ID: 36474183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.